We sought direct evidence for anti-islet cellular cytotoxicity in diabetic Bio-Breeding/Worcester (BB/W) rats by comparing the effects of splenic lyinphoid cells from BB/W diabetic (D), diabetes-prone (DP), and diabetes-resistant (DR) rats on the release of 1(Cr from damaged islet cells in vitro. D 
Introduction
There is increasing recent evidence that the immune system may be involved in the pathogenesis of insulin-dependent diabetes mellitus (IDDM)' in humans as well as in certain animal models. The most extensively studied animal model is the BioBreeding (BB) rat (reviewed in reference 1). This rodent has a MHC, major histocompatibility complex; NK, natural killer, RTIu, MHC-compatible rats; RTIb, RTI5, RTI', and RTI', MHC-incompatible rats; Ta/,, T-cytotoxic/suppressor, WF, Wistar-Furth. spontaneous form of diabetes that makes it a close counterpart of the human subject with IDDM. Obesity is absent, both sexes are affected equally, and the peak incidence of diabetes occurs around the age of sexual maturation (60-120 d). At this time, 30-60% of the rats become diabetic, manifesting severe hyperglycemia, glucosuria, hypoinsulinemia, and ketoacidosis that is lethal if insulin is not administered. Histologic study of acutely diabetic animals reveals intense infiltration of the islets (insulitis) by mononuclear cells (2, 3), mostly activated lymphocytes and macrophages (4) , and chronically diabetic animals have islets devoid selectively of insulin-containing beta cells (2, 5) .
The observation of pancreatic insulitis suggests a cell-mediated immune pathogenesis for diabetes in the BB rat. Furthermore, a variety of immune suppression or enhancement procedures have been reported to prevent and/or cure diabetes in this animal model. BB diabetes-prone (DP) rats have been protected from developing diabetes by neonatal thymectomy (6) , neonatal bone marrow allografts (7, 8) , sublethal whole body irradiation (9) , total lymphoid irradiation (10), administration of antilymphocyte globulin (9) , glucocorticoids (11), and cyclosporine (11, 12) . Also, transfusions of whole blood (13) , or peripheral T lymphocytes (14) from a diabetes-resistant (DR) line of BB rats have been reported to prevent the appearance of diabetes in DP rats. Conversely, concanavalin A (Con A)-activated splenic lymphocytes have been shown to adoptively transfer insulitis and diabetes upon injection into young DP BB/W (Worcester) rats (I5), or into otherwise DR BB/W rats (16) and Wistar-Furth (WF) rats (17) that have been pretreated with cyclophosphamide.
These immunological manipulations of BB rats, therefore, provide strong evidence for the involvement ofcellular immunity in the pathogenesis of diabetes in this animal. In a recent study (18) we demonstrated that splenic lymphoid cells from BB/W diabetic and DP rats could lyse cells and decrease insulin content in monolayer cultures of WF rat islet cells and a rat islet cell line (RIN). In the present study, we have characterized further this cell-mediated cytotoxicity (CMC) to IN) and plasma glucose concentrations exceeded 200 mg/dl. Diabetic rats were treated with a single daily injection of 1-2 U of protamine zinc insulin and were studied within 12 d of diagnosis. DP rats were obtained from the same sublines as the diabetic animals (17-20 generations of brother-sister matings) and were studied at 100-130 d of age. DR rats were age-matched to the DP rats and obtained from BB/W sublines bred for resistance to diabetes. The BB/W diabetic, DP, and DR rats served as sources of splenic lymphoid cells which were used as effector cells in the cytotoxicity assays. Pancreatic islet cells and splenic lymphocytes used as target cells in these assays were isolated from WF rats, major histocompatibility complex (MHC)-compatible (RTIU) with the BB/W rats, and from MHC-incompatible (RTI') Lewis rats. The WF and Lewis rats were inbred, females, 125-150 g body weight, and purchased from Microbiological Assoc., Walkersville, MD.
Splenic lymphocyte isolation. Spleens were removed aseptically from anesthetized rats (sodium pentobarbital 50 mg/kg), then washed twice and disrupted in a glass homogenizer in RPMI-1640 medium (Gibco, Grand Island, NY) supplemented with 100 U/ml penicillin, 100 Mg/ml streptomycin, and 10 mM Hepes (Gibco). The cell suspension was filtered through sterile gauze and transferred to a 50-ml polypropylene centrifuge tube in a final volume of 35 ml. 15 ml of Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) was layered underneath the spleen cells and the cells were centrifuged at 400 g for 30 min. Lymphoid (mononuclear) cells were collected from the interface, washed twice, and resuspended in RPMI medium further supplemented (complete medium) with 10% heat-inactivated fetal calf serum (Gibco). The cells were counted and adjusted to the desired concentrations for direct use as effector cells in the cytotoxicity assays, or further purified on nylon wool or Percoll. Cell viability assessed by trypan blue exclusion was >95%.
Nylon wool purification. BB/W rat splenic lymphoid cells (50-150 X 106 in 2 ml) were incubated in complete medium on nylon wool columns (0.6 g nylon wool per 5-ml syringe) for 1 h at 370C in 95% humidified air/5% CO2. The nonadherent population was eluted in 10 ml of warm medium, washed once, and resuspended to the desired concentrations for use as effector cells in the cytotoxicity assays. In the experiments where nylon wool adherent cells were assayed, these were forced from the columns (after first washing these through with another 10 ml of medium) by pressing the nylon wool with a Pasteur pipette while washing with cold medium.
Percoll purification. BB/W rat splenic lymphoid cells were separated into fractions enriched for either large lymphocytes and monocytes, or small lymphocytes, on discontinuous Percoll gradients. Dulbecco's 10 X phosphate-buffered saline (PBS) was diluted 1: 10 with Percoll (Pharmacia Fine Chemicals) to make a I X Percoll-PBS solution. This solution was then diluted with 1 X PBS to form the 65, 55, and 40% vol/vol working solutions of Percoll for the discontinuous gradients. Splenic lymphoid cells, previously isolated on Ficoll gradients, were suspended in the 65% Percoll solution at a concentration of 10' cells/ml in 15-ml centrifuge tubes. Equal volumes of 55 and 40% Percoll and finally 1 X PBS were subsequently layered on top of each other and the cells centrifuged at 750 g for 15 min. A low density fraction enriched in large lymphocytes and monocytes was recovered from the 40-55% interface, and a high density fraction enriched in small lymphocytes was recovered from the 55-65% interface. Morphologic analysis ofcytospin preparations of Wright's-stained cells revealed that, for diabetic and DP rats, large lymphocytes/monocytes were enriched from 40±6% before Percoll purification (total mononuclear cells) to 68±15% in the low-density Percoll fraction, and small lymphocytes were enriched from 54±5 to 65±2% in the high density fraction; and for DR rats, large lymphocytes/monocytes were enriched from 19±5 to 52±13% in the low density fraction, and small lymphocytes were enriched from 81±5 to 86±4% in the highdensity fraction. Cells identified as large lymphocytes/monocytes included large granular lymphocytes ( (RTIU) and Lewis (RTI') rats, by collagenase digestion (20) . The islets were dissociated into single cells by incubation in Ca2+/Mg2+-free PBS with 3 mM EGTA for 10 min at 37°C, then in PBS with 1 mg/ml trypsin for 10 min at 37°C (21). Splenic lymphocytes were isolated from both WF and Lewis rats by using Ficoll-Hypaque as described above. Several cell lines were also used as targets. The RIN (clone SF) is derived from the New England Deaconess Hospital (RTI1) rat islet cell tumor, and synthesizes and secretes primarily insulin (22) . RIN 
Results
Differential cytotoxic effects of splenic lymphoid cells from BB/W diabetic, DP, and DR rats. Splenic lymphoid cells from BB/W diabetic, DP, and DR rats showed different degrees of CMC in a 5'Cr release assay (Table I) . At a 1:20 target/effector cell ratio, cytolysis ofMHC-compatible WF (RTP) rat islet cells by diabetic spleen cells (9.7±1.1%, P < 0.001) and by DP cells (7.0±1.0%, P < 0.005) was significantly greater than by DR cells (3.5±0.7%). Similarly, cytolysis of MHC-incompatible Lewis (RTI') rat islet cells by diabetic cells (10.7±2.0%, P < 0.005) and by DP cells (8.2±1.0%, P < 0.005) was significantly greater than by DR cells (4.1±0.7%). No appreciable cytotoxicity was observed when WF or Lewis rat spleen cells (Table I ), or Con Aactivated WF rat splenic lymphoblasts (not shown), were used as targets.
Using an islet cell line (RIN) as target, the dose-dependent cytotoxic effects of BB/W rat splenic lymphoid cells were investigated ( Fig. 1) . At a target/effector ratio of 1:20, lysis of RIN cells by diabetic spleen cells (21.4±1.8%, P < 0.001) and by DP cells (14.0+1.7%, P < 0.001) was significantly greater than by DR cells (6.0±0.8%), and the cytotoxic effect of diabetic spleen cells was significantly greater than that of DP cells (P < 0.01). At a target/effector ratio of 1:8, lysis of RIN cells by diabetic cells (11.2±1.4%, P < 0.001) and by DP cells (8.4±0.9%, P < 0.001) was significantly greater than by DR cells (2.0±0.8%). At a target/effector ratio of 1:2, the effects of diabetic, DP, and DR cells did not differ. In contrast to RIN islet cells, rat pituitary cells (GH3 cell line) exhibited low (<6%) and not significantly different levels of lysis by diabetic, DP, and DR splenic effector cells, at all target/effector ratios tested (Fig. 1 ). Identification of cytotoxic cells in BB/W diabetic and DP rats. To determine the nature of the cytotoxic cells from BB/W diabetic rats, Ficoll-isolated splenic cells were incubated on nylon wool columns. The cytotoxic activity against RIN cells, and against WF islet cells, was found mainly in the nylon wool nonadherent population (Table II) . This would exlude macrophages as signficant contributors to islet cell cytotoxicity. In addition, nonadherent splenic cell fractions from diabetic and DP rats were significantly more cytotoxic to RIN islet cells than were the total splenic lymphoid (mononuclear) cells (Table III) . After passage through nylon wool, cytotoxicity to RIN islet cells increased by 51±13% (P < 0.005) for diabetic effector cells, and by 48±14% (P < 0.02) for DP effector cells, while no increase was seen for DR cells. In contrast, passage of the splenic cells through nylon wool did not signficantly increase the small cytotoxic effects ofdiabetic, DP, and DR spleen cells on GH3 target cells. Enrichment for islet-directed cytotoxicity in the nylon wool nonadherent splenic lymphoid cells ofdiabetic and DP rats suggested that the cytotoxic effector cells were T lymphocytes and/ or NK cells. The latter possibility was explored by using an NKsensitive cell line (G1-TC rat thymoma) as a target. GI-TC cells were lysed by diabetic and DP spleen cells in a dose-dependent manner (Fig. 2) . Furthermore, the cytotoxic effects ofindividual rat splenic cell preparations on RIN islet cells were proportional to their effects on G1-TC cells, suggesting that the cells cytotoxic to RIN cells might be NK cells. This possibility was explored further by using another NK-sensitive cell line (YAC-l mouse lymphoma) as target, and by comparing the cytotoxic effects of splenic cells from diabetic, DP, and DR rats on RIN and YAC-1 cells. There was a highly significant correlation between the cytotoxic effects of splenic cells from diabetic, DP, and DR rats on RIN and YAC-1 cells (Fig. 3) . In addition, unlabeled YAC-I cells competed proportionally for the lysis of5"Cr-labeled YAC-1 and RIN cells by diabetic effector cells (Table IV) . This indicated that RIN cells shared a common determinant(s) with the NK-sensitive YAC-l cells, and implied that the cells cytotoxic to RIN islet cells might be NK cells.
Since NK cell cytotoxic activity has been attributed to LGL (25), we separated the Ficoll-isolated total splenic mononuclear cells further on Percoll density gradients into fractions enriched in small lymphocytes or large lymphocytes/monocytes (containing LGL), then tested the separate cell fractions in cytotoxicity assays (Table V) . The large lymphocyte/monocyte cell fractions were significantly more cytotoxic to RIN islet cells than were the total (unfractionated) mononuclear cells from the same animals, for diabetic rats (21±2.4 vs. 7.0±2.3%, P < 0.001), DP rats (15.2±2.4 vs. 8.5±0.7%, P < 0.05), and DR rats (8.0± 1.0 vs. 0.2±1.5%, P < 0.05). Also, the cytotoxic effects of the large lymphocyte/monocyte fractions from diabetic (21.8±2.4%) and DP (15.2±2.4%) rats were significantly higher than that of the large lymphocyte/monocyte fraction from DR rats (8.0±1.0%). In contrast to the significantly increased cytotoxic effects of the large lymphocyte/monocyte fractions using RIN islet cells as targets, cytotoxicity to GH3 pituitary cells remained negligible.
Effects ofan anti-NK cell serum on cytotoxicity ofBB/W rat spleen cells. In order to demonstrate further the NK cell identity of the cytotoxic spleen cells, nylon wool-purified (nonadherent) splenic mononuclear cells from a BB/W diabetic rat were incubated with an antiserum to NK cells (anti-asialo GM 1 serum) and complement, to lyse NK cells, and cytotoxic activity of the cells remaining was assayed (Table VI) . The cytotoxic effects of the diabetic spleen cells were reduced in a dose-dependent fashion after incubation with anti-asialo GM 1 serum and complement, and the reductions in cytotoxicity were similar for YAC-l and RIN targets. A 1:100 dilution of antiserum reduced cytotoxicity to both YAC-I and RIN cells to 12% ofthat effected by diabetic spleen cells treated with complement alone, and this was associated with the removal of -20% ofthe effector cells, indicating that the cytotoxic cells accounted for only a small proportion ofthe diabetic rat splenic lymphoid cells, even after enrichment in a nylon wool nonadherent cell fraction. Effects of an anti-NK cell serum on monoclonal antibodydefined lymphocyte subpopulations and cytotoxicity. In order to assess the effects ofthe anti-NK cell serum used (anti-asialo GM1) on the phenotypic composition of the splenic lymphoid cells from BB/W rats, nylon wool-purified (nonadherent) splenic lymphoid cells were incubated with this antiserum and complement, or complement alone, and then with monoclonal antibodies to the different lymphocyte subsets (Table VII) 18 .7±4.8%, P < 0.001), RIN cells (I15.7±4.9 vs. 6.9±2.3%, P < 0.05), and WF islet cells (9.3±1.4 vs. 3.1±0.9%, P < 0.05). Moreover, these decreases in the cytotoxic effects of the diabetic spleen cells to YAC-1 (56%), RIN (57%), and WF islet cells (67%) were similar to the decreases in proportions of W3/1 3+ OX 19-cells (59%) or OX8+ cells (50%) observed in these same antiserum-treated splenic cell preparations (Table VII) . Table VIII also shows that splenic cells (control) from diabetic rats were significantly more cytotoxic to YAC-1 (P < 0.001), RIN (P < 0.05), and WF islet cells (P < 0.005) than splenic cells (control) from DR rats. Also, the low levels of cytotoxicity delivered by DR spleen cells were completely eliminated by anti-asialo GM1 serum (Table VIII) , and this was accompanied by the total removal of W3/ 13+ OX 19-cells by this antiserum (Table VII) .
Discussion
In a recent study (18) we demonstrated that splenic lymphoid cells from BB/W diabetic and DP rats could lyse cells and decrease insulin content in monolayer cultures ofWF rat islet cells and a rat islet cell line (RIN). In the present study, we demonstrate that splenic lymphoid cells from BB/W diabetic rats, and to a lesser extent DP rats, can lyse MHC-compatible WF (RTIU) rat islet cells, as well as MHC-incompatible Lewis (RTI') rat islet cells and RIN cells derived from an islet tumor in a New England Deaconess Hospital rat (RTI9). Neither WF or Lewis splenic lymphocytes nor rat pituitary cells (GH3 line) were lysed by splenic cells from diabetic or DP rats. These studies provide data in vitro to support the hypothesis that a cell-mediated anti-islet immune response is involved in the destruction of islet beta cells resulting in diabetes in the BB rat. (30) .
Although these data provide the first evidence that NK cell numbers and activity are increased in BB DP and diabetic rats, this observation is supported by earlier studies. Since the now well-documented generalized T-lymphopenia (in blood, lymph nodes, spleen, and thymus) was first described in BB DP and diabetic rats, it has been recognized that these rats possess a significantly greater subpopulation(s) of lymphoid cells not identified by available monoclonal antibodies for T and B lymphocyte subsets. Recently, an increase in a subpopulation of large thymocytes has been reported in BB DP rats (31) . This cell population was identified to have the monoclonal antibody-defined phenotype W3/13+ OX8+ OX19-W3/25-(31), and this phenotype identifies NK cells in rats ofdifferent strains (28, 29), including BB/W rats (30, 32) . The reason(s) for the increases in NK cells in BB diabetic and DP rats are not clear. This could be associated with the T cell-deficient state existent in the BB DP rat, by analogy to the findings of increased NK activity in athymic nude mice (33) and rats (26). A defect in thymocyte maturation has been suggested as a cause of the T lymphopenia observed in BB DP rats (1) . This may then be associated with an increase in immature T cells. Indeed, we observed that many of the splenic cells from diabetic and DP animals identified as large lymphocytes/monocytes included, in addition to LGL (NK cells), immature lymphoid and/or lymphoblastic cells. Immature mouse T cells have been reported to bear asialo GMl determinants (19) and, therefore, removal of such cells by treatment with anti-asialo GM 1 serum in our experiments may have contributed to the decrease in islet-directed cytotoxicity observed. Therefore, we must consider the possibility that the W3/13+ OX 19-population identified to contain NK cells may include immature T cells, and that the latter may have participated in the islet-directed cytotoxicity observed.
Previous studies have shown that activation of BB/W rat spleen cells with Con A is required for the effector cells to passively transfer diabetes in vivo (15) (16) (17) . Similarly, we have demonstrated that cytotoxic effects of BB/W diabetic spleen cells against RIN islet cells in vitro is increased after preincubation of the diabetic effector cells with Con A (18) . Although these observations implicate activated T cells in the cytotoxic process, it should be noted that NK cells as well as T cells can be activated by, and proliferate in response to, the T cell growth factor interleukin 2 (34), a byproduct of Con A stimulation.
Whereas the present study demonstrates that BB/W diabetic and DP rats have increased NK cell-mediated cytotoxicity, it is difficult to explain the islet-directed cytotoxicity within the classical definition ofNK cell target specificities. The (36, 37) , and by the fact that we did not detect lysis of allogeneic (Lewis) lymphocytes by splenic cells from BB/W diabetic or DP rats. These observations suggest that the cells responsible for the killing of WF and Lewis islet cells are one and the same. The islet-directed cytotoxic cells are likely to be NK cells, since the killing of WF islet cells, RIN islet cells, and YAC-l cells were similarly reduced after treatment with anti-asialo GM 1 serum, and since this was associated with proportional reductions in monoclonal antibodydefined populations containing NK cells (W3/13+ OX 19-and OX8+). Lastly, it is becoming apparent that NK activity measured in vitro reflects the participation of several distinct subpopulations with different target specificities, and evidence for nonlymphoreticular targets for NK cells is beginning to emerge (38) .
Some evidence for cell-mediated immunity has been obtained also in human subjects with IDDM. Lymphocyte mediation of islet cell destruction has been suggested by cytotoxicity assays in vitro (39) . These studies in human IDDM require confirmation, however, and further identification of the putative islet cytotoxic cell(s) remains to be completed. In contrast to the BB rat, human subjects do not demonstrate lymphopenia or defects in proportions of T and B lymphocytes (40) . Abnormalities of peripheral blood lymphocyte subpopulations have been reported, however, and these include decreased T-suppressor cell numbers and activity (41) (42) (43) , the presence of activated (Ia+) T cells (44, 45) , and increased killer cells (46) and killer cell activity (47) . Killer cells are responsible for antibodydependent cell-mediated cytotoxicity. NK cells, however, can also mediate this function, and NK and killer activities appear to be two manifestations of the same cell (48) .
In summary, we have demonstrated that NK cell activity is increased in BB/W acutely diabetic and DP rats, and that islet cells can serve as targets for these NK cells in vitro. Clearly, we have no direct evidence that diabetes mellitus is an NK cellmediated disease in the BB rat. Since NK activity and isletdirected cytotoxicity were detected in nondiabetic, DP rats, although at lower levels than in acutely diabetic rats, it appears that NK cells per se, may be insufficent to cause islet beta cell destruction and diabetes. However, BB DP rats, although not hyperglycemic and glucosuric, may manifest varying degrees of glucose intolerance and insulitis (49) . Therefore, it remains to be determined whether the present findings ofincreased NK cell cytotoxicity to islets in vitro may contribute to the development of insulitis and diabetes in the BB rat in vivo. That this may occur is suggested by the recent reports that virtually all OX8+ cells in DP and acutely diabetic BB/W rats are phenotypic NK cells (30) , and treatment of young DP BB/W rats with OX8 monoclonal antibody can prevent the appearance ofdiabetes in these animals (50) .
